102 related articles for article (PubMed ID: 4725373)
1. Decrease in oncogenic potential of L1210 leukemia by triazenes.
Schmid FA; Hutchison DJ
Cancer Res; 1973 Sep; 33(9):2161-5. PubMed ID: 4725373
[No Abstract] [Full Text] [Related]
2. Chemotherapeutic, carcinogenic, and cell-regulatory effects of triazenes.
Schmid FA; Hutchison DJ
Cancer Res; 1974 Jul; 34(7):1671-5. PubMed ID: 4833916
[No Abstract] [Full Text] [Related]
3. Antigenic changes of L1210 leukemia in mice treated with 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide.
Bonmassar E; Bonmassar A; Vadlamudi S; Goldin A
Cancer Res; 1972 Jul; 32(7):1446-50. PubMed ID: 4402275
[No Abstract] [Full Text] [Related]
4. Biology and karyology of murine leukemia L1210 xenografted to the hamster.
Goldenberg DM
Cancer Res; 1972 Apr; 32(4):813-24. PubMed ID: 5014792
[No Abstract] [Full Text] [Related]
5. Cell-mediated response to a mouse leukemic subline antigenically altered following drug treatment in vivo.
Nicolin A; Bini A; Franco P; Goldin A
Cancer Chemother Rep; 1974; 58(3):325-30. PubMed ID: 4841716
[No Abstract] [Full Text] [Related]
6. DNA methylating activity in murine lymphoma cells treated with xenogenizing chemicals.
Puccetti P; Allegrucci M; Borri Voltattorni C; Romani L; Dominici P; Fioretti MC
Cancer Detect Prev Suppl; 1987; 1():311-6. PubMed ID: 2446756
[TBL] [Abstract][Full Text] [Related]
7. Collateral sensitivity of resistant lines of mouse leukemias L1210 and L5178Y.
Schmid FA; Hutchison DJ
Cancer Res; 1972 Apr; 32(4):808-12. PubMed ID: 5014791
[No Abstract] [Full Text] [Related]
8. [Depression of the immune response to lymphoma allotransplant with the use of 5-(3,3-dimethyl-1-triazeno)-imidazol-4-carboxamide (DTIC)].
Giampietri A; Puccetti P; Circolo A; Menconi E
Boll Soc Ital Biol Sper; 1977 Jun; 53(11):922-6. PubMed ID: 597414
[No Abstract] [Full Text] [Related]
9. The return of antimetabolite sensitivity in methotrexate- and 6-mercaptopurine-resistant L1210 murine leukemia by the process of adaptive selection.
Wallerstein H; Slater LM; Eng B; Calman N
Cancer Res; 1972 Oct; 32(10):2235-40. PubMed ID: 5080766
[No Abstract] [Full Text] [Related]
10. Central inhibition of cellular immunity to leukemia L1210 by isoantibody.
Mitchell MS
Cancer Res; 1972 Apr; 32(4):825-31. PubMed ID: 4622583
[No Abstract] [Full Text] [Related]
11. Adoptive immunotherapy in BALB-c times DBA-2 Cr F1 mice bearing an immunogenic subline of L1210 leukemia.
Nicolin A; Canti G; Goldin A
Cancer Res; 1974 Nov; 34(11):3044-8. PubMed ID: 4424774
[No Abstract] [Full Text] [Related]
12. Differences in the immunogenicity of leukemia L1210 sublines in DBA-2 mice.
Mihich E; Kitano M
Cancer Res; 1971 Dec; 31(12):1999-2003. PubMed ID: 5120297
[No Abstract] [Full Text] [Related]
13. Potential anticancer agents. XXII. Pharmacological properties of some new triazene derivatives.
Ionescu D; Neagu V; Dobre V; Niculescu-Duvaz I
Neoplasma; 1981; 28(1):19-26. PubMed ID: 7279057
[TBL] [Abstract][Full Text] [Related]
14. Studies on a cell line derived from the L1210 murine leukemia with altered surface properties and decreased capacity for tumor production.
Kessel D; Bosmann HB
Cancer Res; 1974 Mar; 34(3):603-8. PubMed ID: 4855835
[No Abstract] [Full Text] [Related]
15. Attempt to alter antigenic structure of normal tissues by treatment with dimethyl-triazeno-imidazole-carboxamide in vivo.
Nicolin A; Fagnani R; Nicolotti G; Goldin A
Experientia; 1976 Jun; 32(6):741-2. PubMed ID: 780128
[TBL] [Abstract][Full Text] [Related]
16. Working session report: in vivo-in vitro screening.
Venditti JM
Cancer Chemother Rep 3; 1972 May; 3(1):57-62. PubMed ID: 5049711
[No Abstract] [Full Text] [Related]
17. Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia.
Li LH; Olin EJ; Buskirk HH; Reineke LM
Cancer Res; 1970 Nov; 30(11):2760-9. PubMed ID: 5487063
[No Abstract] [Full Text] [Related]
18. Growth in vitro of L-1210 leukemia in suspension culture.
Kisielow P
Arch Immunol Ther Exp (Warsz); 1970; 18(4):491-9. PubMed ID: 5483306
[No Abstract] [Full Text] [Related]
19. Mechanism of action and pharmacology studies with DTIC (NSC-45388).
Loo TL; Housholder GE; Gerulath AH; Saunders PH; Farquhar D
Cancer Treat Rep; 1976 Feb; 60(2):149-52. PubMed ID: 1260772
[No Abstract] [Full Text] [Related]
20. Antileukemic synergism between cyclophosphamide and an antitumor platinum compound.
Walker EM; Gale GR
Res Commun Chem Pathol Pharmacol; 1973 Sep; 6(2):419-25. PubMed ID: 4750093
[No Abstract] [Full Text] [Related]
[Next] [New Search]
